Drug Trial News

RSS

Clinical trial of Grafix for treatment of chronic diabetic foot ulcers accepted for presentation at SAWC

Osiris Therapeutics, Inc. (NASDAQ: OSIR), announced today that its multi-center, randomized, controlled clinical trial evaluating the safety and effectiveness of Grafix® for the treatment of chronic diabetic foot ulcers has been accepted for podium presentation at the upcoming Symposium on Advanced Wound Care (SAWC) in Las Vegas on Friday, September 27, 2013.

7 Sep 2013

Viamet initiates phase 2 clinical trial of antifungal agent VT-1161 for treatment of vulvovaginal candidiasis

Viamet Pharmaceuticals, Inc. announced today the initiation of the phase 2 clinical program for its antifungal agent VT-1161. The initial phase 2 study is designed to evaluate the safety and efficacy of VT-1161 in the treatment of vulvovaginal candidiasis (VVC) and is being conducted at leading clinical centers in the United States.

7 Sep 2013

Cellular Biomedicine Group reports interim results of Phase I/IIa clinical trial for Knee Osteoarthritis

Cellular Biomedicine Group, Inc. today announced the interim results of its Phase I/IIa clinical trial for human adipose-derived mesenchymal precursor cell (haMPC) therapy for Knee Osteoarthritis, which tests the safety and efficacy of intra-articular injections of autologous (patient's own) haMPCs in order to reduce inflammation and repair damaged joint cartilage.

6 Sep 2013

$Pivotal Study Supports Use of IMNOVID®▼ Pomalidomide in Patients with Relapsed or Refractory Multiple Myeloma$

Pivotal Study Supports Use of IMNOVID®▼ Pomalidomide in Patients with Relapsed or Refractory Multiple Myeloma

The Lancet Oncology published this week findings from a study, which showed that the new oral therapy IMNOVID®▼ (pomalidomide), used in combination with low-dose dexamethasone demonstrated a significant survival advantage over high-dose dexamethasone alone, in patients with relapsed and refractory multiple myeloma (rrMM).1

5 Sep 2013

Rigel plans to focus on completing three clinical programs for ITP, DLE and dry eye disease

Rigel Pharmaceuticals, Inc. today announced its plans to focus the Company's resources on the completion of three lead clinical programs. These efforts include commencing a Phase 3 clinical study of fostamatinib, an oral SYK inhibitor, in Immune Thrombocytopenic Purpura pending discussions with regulatory agencies.

5 Sep 2013

Elan enrolls first patient dosing in phase 2a study of ELND005 in Down syndrome

Elan Corporation, plc (NYSE: ELN) announced today the first patient dosing in a Phase 2a study of ELND005 in Down syndrome. Study ELND005-DS201 will evaluate the safety and pharmacokinetics of 2 doses of ELND005 and placebo in young adults with Down syndrome without dementia, and will also include select cognitive and behavioural measures.

5 Sep 2013

Affinium initiates dosing in Phase 1 IV clinical trial of antibiotic prodrug, AFN-1720

Affinium Pharmaceuticals announced today that it has initiated dosing in a Phase 1 intravenous clinical trial of its new antibiotic prodrug, AFN-1720. AFN-1720 is the prodrug of the active drug, AFN-1252.

5 Sep 2013

Endo, BDSI complete interim analyses of Phase III trials for BEMA Buprenorphine

Endo Pharmaceuticals Inc., a subsidiary of Endo Health Solutions Inc., and BioDelivery Sciences International, Inc. announced today that the companies have completed interim analyses of both the opioid naive and opioid experienced Phase III trials for BEMA Buprenorphine.

4 Sep 2013

University of Leeds to study mechanism of Prana’s PBT434 in animal models of Parkinson’s disease

Prana Biotechnology today announced that Parkinson’s UK has awarded £150,000 (AU$260,000) to The University of Leeds to study the mechanism of action of PBT434.

4 Sep 2013

RVX-208 drug fails to increase good cholesterol levels in ASSURE trial

Patients with coronary artery disease and low levels of "good cholesterol - or high-density lipoprotein - who were treated with a drug designed to increase HDL levels and reduce coronary plaque build-up, experienced no better results than those treated with placebo, according to research conducted by the Cleveland Clinic Coordinating Center for Clinical Research.

4 Sep 2013

Scientists identify new drugs that have potential to slow down progression of Parkinson's

New drugs which may have the potential to stop faulty brain cells dying and slow down the progression of Parkinson's, have been identified by scientists in a pioneering study which is the first of its kind.

4 Sep 2013

Esperion Therapeutics reports positive results from ETC-1002 Phase 2a study for LDL-C treatment

Esperion Therapeutics, Inc., a clinical-stage biopharmaceutical company, today announced positive top-line results from a Phase 2a study of ETC-1002 when added to statin therapy in patients with elevated levels of low density lipoprotein cholesterol (LDL-C or "bad cholesterol").

4 Sep 2013

Apitope successfully completes ATX-MS-1467 Phase I trial in relapsing MS patients with positive results

Apitope, the drug discovery and development company focused on treating the underlying cause of autoimmune diseases, today announced completion with positive results of its second Phase I clinical trial of ATX-MS-1467.

3 Sep 2013

Prana's PBT2 drug recognised as one of the most promising treatments under development

Prana Biotechnology, a leading global developer of first-in-class treatments for neurodegenerative disease, is pleased to announce Elsevier Business Intelligence has named clinical drug PBT2 as one of the Top 10 Neuroscience Projects to Watch.

3 Sep 2013

Imaxio's pro-immunogenic technology used in tuberculosis vaccine phase I clinical study

Imaxio, a biopharmaceutical company specializing in vaccines and genomics, announces today that IMX313, its proprietary pro-immunogenic technology, has been administered for the first time in humans in a tuberculosis vaccine phase I clinical study. The trial is being conducted by the Jenner Institute at Oxford University, England.

3 Sep 2013

Omecamtiv mecarbil fails to achieve primary endpoint in phase II ATOMIC-AHF study

Omecamtiv mecarbil, a cardiac myosin-activator, did not achieve its primary efficacy endpoint in reducing dyspnoea (shortness of breath) in patients with acute heart failure, according to the results of the phase II ATOMIC-AHF (Acute Treatment with Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure) study.

3 Sep 2013

Acacia Pharma raises $23.5 million in Series B financing

Acacia Pharma, a pharmaceutical company specialising in the development of drugs for supportive care, announces it has raised £15 million (~$23.5 million) in a Series B financing led by Fidelity Biosciences and Novo A/S.

3 Sep 2013

Anti-diabetic drug alogliptin meets primary endpoint in EXAMINE trial

Patients with type 2 diabetes and high cardiovascular risk due to recent acute coronary syndromes had similar rates of cardiovascular events when treated with the anti-diabetic agent alogliptin compared to placebo according to results of the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care trial presented at the European Society of Cardiology Congress.

2 Sep 2013

Debiopharm starts Debio 1347 phase I study in patients with advanced solid tumors

Debiopharm Group, the Swiss-based global biopharmaceutical company that focuses on the development of prescription drugs that target unmet medical needs including oncology, today announced the start of a phase I, open label multicenter study of a selective FGFR 1, 2, 3 inhibitor, Debio 1347 (CH5183284) in patients with advanced solid tumors.

2 Sep 2013

Ipsen announces results of phase III study of somatuline in patients with neuroendocrine tumors

Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the detailed results of phase III CLARINET study assessing the effect of Somatuline® Autogel® 120 mg in patients with gastrointestinal and pancreatic neuroendocrine tumors ("GEP-NETs")1 will be disclosed for the first time on September 28, 2013 at the European Cancer Congress 2013 (Sept. 27 - Oct. 1, 2013) in Amsterdam.

31 Aug 2013

Drug Trial News

Clinical trial of Grafix for treatment of chronic diabetic foot ulcers accepted for presentation at SAWC

Viamet initiates phase 2 clinical trial of antifungal agent VT-1161 for treatment of vulvovaginal candidiasis

Cellular Biomedicine Group reports interim results of Phase I/IIa clinical trial for Knee Osteoarthritis

Pivotal Study Supports Use of IMNOVID®▼ Pomalidomide in Patients with Relapsed or Refractory Multiple Myeloma

Rigel plans to focus on completing three clinical programs for ITP, DLE and dry eye disease

Elan enrolls first patient dosing in phase 2a study of ELND005 in Down syndrome

Affinium initiates dosing in Phase 1 IV clinical trial of antibiotic prodrug, AFN-1720

Endo, BDSI complete interim analyses of Phase III trials for BEMA Buprenorphine

University of Leeds to study mechanism of Prana’s PBT434 in animal models of Parkinson’s disease

RVX-208 drug fails to increase good cholesterol levels in ASSURE trial

Scientists identify new drugs that have potential to slow down progression of Parkinson's

Esperion Therapeutics reports positive results from ETC-1002 Phase 2a study for LDL-C treatment

Apitope successfully completes ATX-MS-1467 Phase I trial in relapsing MS patients with positive results

Prana's PBT2 drug recognised as one of the most promising treatments under development

Imaxio's pro-immunogenic technology used in tuberculosis vaccine phase I clinical study

Omecamtiv mecarbil fails to achieve primary endpoint in phase II ATOMIC-AHF study

Acacia Pharma raises $23.5 million in Series B financing

Anti-diabetic drug alogliptin meets primary endpoint in EXAMINE trial

Debiopharm starts Debio 1347 phase I study in patients with advanced solid tumors

Ipsen announces results of phase III study of somatuline in patients with neuroendocrine tumors

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News